To understand how TET1 expression inhibits ovarian cancer growth, we performed a genome-wide RNA-seq analysis of total mRNA isolated from ES-2 cells treated with paclitaxel (0.01 μg/mL) (EVTAXOL) or without it (EV) for 24 h and from TET1-overexpressing ES-2 (ET) or empty vector-carrying (EV) cells (Figure 6A). This evidence concerns the gene TET1 and ovarian carcinoma.